The key role of altered tubule cell lipid metabolism in kidney disease development.

Acute kidney injury (AKI) chronic kidney disease (CKD) de novo lipogenesis fatty acid oxidation lipid metabolism

Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
11 Apr 2024
Historique:
received: 26 02 2023
revised: 16 02 2024
accepted: 27 02 2024
medline: 14 4 2024
pubmed: 14 4 2024
entrez: 13 4 2024
Statut: aheadofprint

Résumé

Kidney epithelial cells have very high energy requirements, which are largely met by fatty acid oxidation. Complex changes in lipid metabolism are observed in patients with kidney disease. Defects in fatty acid oxidation and increased lipid uptake, especially in the context of hyperlipidemia and proteinuria, contribute to this excess lipid build-up and exacerbate kidney disease development. Recent studies have also highlighted the role of increased de novo lipogenesis in kidney fibrosis. The defect in fatty acid oxidation will cause energy starvation. Increased lipid uptake, synthesis and lower fatty acid oxidation can cause toxic lipid build-up, reactive oxygen species generation, and mitochondrial damage. Better understanding of these metabolic processes may open new treatment avenues for kidney diseases by targeting lipid metabolism.

Identifiants

DOI: 10.1016/j.kint.2024.02.025 PMID: 38614389
pubmed: 38614389
pii: S0085-2538(24)00252-7
doi: 10.1016/j.kint.2024.02.025
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Lauren E Lee (LE)

Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of; Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA; Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Genetics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA; Penn-CHOP Kidney Innovation Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA.

Tomohito Doke (T)

Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of; Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA; Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Genetics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA; Penn-CHOP Kidney Innovation Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA.

Dhanunjay Mukhi (D)

Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of; Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA; Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Genetics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA; Penn-CHOP Kidney Innovation Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA.

Katalin Susztak (K)

Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of; Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA; Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Genetics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA; Penn-CHOP Kidney Innovation Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA. Electronic address: ksusztak@pennmedicine.upenn.edu.

Classifications MeSH